MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Hutchison China MediTech Ltd ADR

Fermé

SecteurSoins de santé

15.73 1.16

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.46

Max

15.81

Chiffres clés

By Trading Economics

Revenu

6M

Ventes

162M

P/E

Moyenne du Secteur

75.25

40.527

Marge bénéficiaire

3.676

Employés

1,811

EBITDA

-5M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+32.89% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.6B

Ouverture précédente

14.57

Clôture précédente

15.73

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juil. 2025, 23:45 UTC

Acquisitions, Fusions, Rachats

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 juil. 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 23:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 juil. 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3 juil. 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 juil. 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 juil. 2025, 22:21 UTC

Résultats

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 juil. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 juil. 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3 juil. 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 juil. 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious -2-

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 juil. 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3 juil. 2025, 15:47 UTC

Résultats

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 juil. 2025, 15:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Comparaison

Variation de prix

Hutchison China MediTech Ltd ADR prévision

Objectif de Prix

By TipRanks

32.89% hausse

Prévisions sur 12 Mois

Moyen 20.85 USD  32.89%

Haut 27 USD

Bas 14.7 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

14.24 / 14.78Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.